During the corresponding time, Agenus Inc recorded a revenue increase by 34.36 % year on year, sequentially revenue grew by 2.32 %. While revenue at the Agenus Inc's corporate clients
Agenus Inc's Comment on Sales, Marketing and Customers
The company depends on third-party manufacturers and suppliers for producing clinical and commercial supplies of its product candidates. It does not have long-term supply agreements with all required vendors, exposing it to risks such as supply interruptions, delays, and increased costs. The company is required to make significant non-refundable deposits to secure manufacturing slots and may be obligated to purchase minimum quantities, which could result in financial losses if sales forecasts are not met. Additionally, reliance on third parties involves risks related to regulatory compliance, quality assurance, and potential breaches of manufacturing agreements.
In the rapidly evolving field of immuno-oncology, Agenus Inc. (Nasdaq: AGEN) has marked a significant milestone with the presentation of new data demonstrating promising survival outcomes for patients with advanced-stage cancer undergoing treatment with a combination of botensilimab (BOT) and balstilimab (BAL). This novel therapeutic combination has emerged as a potential beacon of hope for patients grappling with multiple refractory solid tumors, showcased at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Overview of Botensilimab and BalstilimabBotensilimab is an advanced multifunctional, Fc-enhanced CTLA-4 antibody, designed to augment the immune response against cancer...
: The landscape of hepatocellular carcinoma (HCC) treatment continues to evolve with the ongoing developments in immuno-oncology. Agenus Inc. has made significant strides with its dual therapy of botensilimab (BOT) and balstilimab (BAL), which demonstrates promise in pretreated, difficult-to-treat liver cancer patients. This article reviews the latest findings from the Phase 1 study presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, along with the company’s financial performance and projections for the future. Hepatocellular carcinoma, a prevalent and aggressive form of liver cancer, often poses significant treatment challenges, particularly for patients with pre-exist...
The Efficacy of Botensilimab in Treatment-Resistant Cancers: Insights from Recent Research The development of novel immunotherapies has transformed the landscape of cancer treatment, particularly for advanced and treatment-resistant malignancies. One such promising candidate is botensilimab, a multifunctional anti-CTLA-4 antibody being investigated by Agenus Inc. This article synthesizes insights from a seminal study published in Cancer Discovery, highlighting botensilimab’s unique mechanism of action, its effectiveness in treatment-resistant cancers, and the implications of these findings for future cancer therapeutics. Cancer remains one of the leading causes of morbidity and mortality worldwide. ...
In recent years, substantial progress has been made in the field of immunotherapy for cancer treatment, revolutionizing the way we approach various malignancies. One such breakthrough is the combination of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colon cancer. This article aims to summarize and analyze the recent investigator-sponsored trial (IST) conducted by Agenus Inc, which revealed remarkable tumor reductions in patients with microsatellite-stable (MSS) colon cancer. The study findings were presented at the 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, Germany.Overview of the Study:The IST, led by Dr. Pashtoon Kasi, enrolled a...
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual MeetingLEXINGTON, Mass. - Agenus Inc. (Agenus), a leading developer of immunological agents for cancer treatment, has announced that a novel analysis from the Phase 1b trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024.The presentation at the ASCO Annual Meeting will provide important insights into the potential of botensilimab and balstilimab combination therapy for patients with relapsed...
In an exciting development for the field of cancer treatment, Agenus Inc., a prominent biotechnology company specializing in groundbreaking immunological agents, has announced its plans to conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA). The meeting aims to discuss the potential use of botensilimab plus balstilimab (BOT/BAL) combination therapy in patients suffering from relapsed or refractory metastatic colorectal cancer (mCRC) that is not microsatellite instability-high or deficient mismatch repair (dMMR) (r/r MSS mCRC). Concurrently, Agenus Inc. has also witnessed a remarkable increase in revenue, growing by 20.88% year on year, with a sequential gro...
Agenus Inc., a renowned developer of innovative immunological agents for cancer treatment, has recently announced the selection of its botensilimab and balstilimab combination data for presentation at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO). This significant development highlights the company s ongoing efforts to address the unmet needs of patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM). In addition to this positive news, Agenus Inc. has also witnessed a notable growth in revenue over the past year. Agenus Inc. disclosed that its Phase 1b trial for botensilimab in combination with balstilimab (BOT/...
Agenus Inc’s Comment on Sales, Marketing and Customers
The company depends on third-party manufacturers and suppliers for producing clinical and commercial supplies of its product candidates. It does not have long-term supply agreements with all required vendors, exposing it to risks such as supply interruptions, delays, and increased costs. The company is required to make significant non-refundable deposits to secure manufacturing slots and may be obligated to purchase minimum quantities, which could result in financial losses if sales forecasts are not met. Additionally, reliance on third parties involves risks related to regulatory compliance, quality assurance, and potential breaches of manufacturing agreements.
Sources:
Agenus Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Agenus Inc’s corporate clients.
For your research, we’ve provided 9 tables on Agenus Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
31.76 %